Redefining the Lymphadenectomy Standard to Avoid Understaging in Oncologic Colectomies

Area of Science:

• Oncology
• Surgical Pathology
• Cancer Staging

Background:

• Accurate lymph node staging post-colectomy is crucial for adjuvant chemotherapy decisions in nonmetastatic colon cancer.
• The current standard for lymph node examination has not been updated in decades.
• This study aimed to establish a data-driven lymph node threshold for optimized oncologic outcomes.

Purpose of the Study:

• To identify an optimal lymph node examination threshold for colon cancer staging.
• To evaluate the association between lymph node count and oncologic outcomes.
• To inform updated guidelines for lymph node examination in colectomy specimens.

Main Methods:

• Utilized the National Cancer Database (NCDB) for patients with clinically node-negative colon adenocarcinoma (2010-2021).
• Analyzed variables associated with nodal positivity and likelihood of positivity with increasing lymph node examination targets.
• Compared outcomes based on the number of examined lymph nodes.

Main Results:

• 26.3% of clinically node-negative patients were pathologically node-positive.
• Nodal positivity was linked to lymphovascular invasion, poor differentiation, microsatellite instability, younger age, and sigmoid tumors.
• Examining ≥18 lymph nodes correlated with higher rates of identifying pathologic nodal positivity, receiving adjuvant chemotherapy, and improved overall survival compared to 12-17 nodes.

Conclusions:

• A higher lymph node examination target (≥18 nodes) is superior to the current standard for colon cancer staging.
• This increased target improves the detection of Stage III disease.
• Adopting a higher lymph node count is associated with increased adjuvant chemotherapy use and better overall survival.